The appropriate use of Tiered virus panels when assessing HIV-1 vaccine-elicited neutralizing antibodies

Watch the Webinar


Based on their in vitro sensitivity to monoclonal antibodies and sera of infected individuals, molecular clones of HIV-1 are subdivided into Tiers, with Tier 1 viruses being the most sensitive to neutralization, Tier 2 being moderately sensitive, and Tier 3 the most resistant. Panels of Tiered viruses are used by researchers to evaluate and compare the levels of neutralizing antibody responses in preclinical and clinical studies. Even though the majority of the circulating HIV-1 variants (a logical target for an effective vaccine) are rated as Tier 2, no vaccine candidate to date has been able to elicit broad neutralizing responses against Tier 2 viruses. Partly as a result of this challenge, researchers often resort to measuring neutralization of Tier 1 viruses. There is a need to better define what information is obtained with neutralization panels of Tier 1 viruses, review how it compares to information from panels of Tier 2 and Tier 3 viruses, and discuss how such information should be used.

The Global HIV Vaccine Enterprise is organizing a one-day workshop bringing together key experts in the field to discuss these questions. The exact agenda for the meeting is still being developed, but it will likely include 2-3 short presentations with most of the time left for discussion. Given the relevance of this topic and the short notice for this convening, we will also webcast the meeting live to allow a broader audience to weigh in in the discussions.

Date: 7 July 2016

New York Marriott Downtown
85 West Street at Albany Street
New York, New York 10006 USA

The output of the meeting will be communicated to the larger community through a paper submitted to a scientific journal and an abstract to the HIVR4P 2016 conference.

If you would like to attend this meeting, please register here.

To join this meeting remotely, please register for the webcast here.

If you have any questions about the meeting, please contact Gabriella Scarlatti at [email protected]

Global HIV Vaccine Enterprise, 64 Beaver Street, # 352, New York, NY 10004 | +1 212-461-3692 or toll free at +1-866-966-4483
All Content ©2005 - 2013 Global HIV Vaccine Enterprise   |   Terms of Use   |   Privacy Policy   |   Log In / My Account